Silence Therapeutics PLC
OTC:SLNCF

Watchlist Manager
Silence Therapeutics PLC Logo
Silence Therapeutics PLC
OTC:SLNCF
Watchlist
Price: 5.6 USD -3.11% Market Closed
Market Cap: 786.2m USD
Have any thoughts about
Silence Therapeutics PLC?
Write Note

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of SLNCF.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SLNCF Intrinsic Value
Not Available
Base Case Scenario
How do you feel about SLNCF?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Silence Therapeutics PLC

Provide an overview of the primary business activities
of Silence Therapeutics PLC.

What unique competitive advantages
does Silence Therapeutics PLC hold over its rivals?

What risks and challenges
does Silence Therapeutics PLC face in the near future?

Summarize the latest earnings call
of Silence Therapeutics PLC.

Show all valuation multiples
for Silence Therapeutics PLC.

Provide P/S
for Silence Therapeutics PLC.

Provide P/E
for Silence Therapeutics PLC.

Provide P/OCF
for Silence Therapeutics PLC.

Provide P/FCFE
for Silence Therapeutics PLC.

Provide P/B
for Silence Therapeutics PLC.

Provide EV/S
for Silence Therapeutics PLC.

Provide EV/GP
for Silence Therapeutics PLC.

Provide EV/EBITDA
for Silence Therapeutics PLC.

Provide EV/EBIT
for Silence Therapeutics PLC.

Provide EV/OCF
for Silence Therapeutics PLC.

Provide EV/FCFF
for Silence Therapeutics PLC.

Provide EV/IC
for Silence Therapeutics PLC.

What are the Revenue projections
for Silence Therapeutics PLC?

How accurate were the past Revenue estimates
for Silence Therapeutics PLC?

What are the Net Income projections
for Silence Therapeutics PLC?

How accurate were the past Net Income estimates
for Silence Therapeutics PLC?

What are the EPS projections
for Silence Therapeutics PLC?

How accurate were the past EPS estimates
for Silence Therapeutics PLC?

What are the EBIT projections
for Silence Therapeutics PLC?

How accurate were the past EBIT estimates
for Silence Therapeutics PLC?

Compare the revenue forecasts
for Silence Therapeutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Silence Therapeutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Silence Therapeutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Silence Therapeutics PLC compared to its peers.

Compare the P/E ratios
of Silence Therapeutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Silence Therapeutics PLC with its peers.

Analyze the financial leverage
of Silence Therapeutics PLC compared to its main competitors.

Show all profitability ratios
for Silence Therapeutics PLC.

Provide ROE
for Silence Therapeutics PLC.

Provide ROA
for Silence Therapeutics PLC.

Provide ROIC
for Silence Therapeutics PLC.

Provide ROCE
for Silence Therapeutics PLC.

Provide Gross Margin
for Silence Therapeutics PLC.

Provide Operating Margin
for Silence Therapeutics PLC.

Provide Net Margin
for Silence Therapeutics PLC.

Provide FCF Margin
for Silence Therapeutics PLC.

Show all solvency ratios
for Silence Therapeutics PLC.

Provide D/E Ratio
for Silence Therapeutics PLC.

Provide D/A Ratio
for Silence Therapeutics PLC.

Provide Interest Coverage Ratio
for Silence Therapeutics PLC.

Provide Altman Z-Score Ratio
for Silence Therapeutics PLC.

Provide Quick Ratio
for Silence Therapeutics PLC.

Provide Current Ratio
for Silence Therapeutics PLC.

Provide Cash Ratio
for Silence Therapeutics PLC.

What is the historical Revenue growth
over the last 5 years for Silence Therapeutics PLC?

What is the historical Net Income growth
over the last 5 years for Silence Therapeutics PLC?

What is the current Free Cash Flow
of Silence Therapeutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Silence Therapeutics PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Silence Therapeutics PLC

Balance Sheet Decomposition
Silence Therapeutics PLC

Current Assets 90.7m
Cash & Short-Term Investments 50.3m
Receivables 38.3m
Other Current Assets 2.1m
Non-Current Assets 9.4m
Long-Term Investments 293k
PP&E 832k
Intangibles 28k
Other Non-Current Assets 8.2m
Current Liabilities 9.2m
Other Current Liabilities 9.2m
Non-Current Liabilities 63.2m
Other Non-Current Liabilities 63.2m
Efficiency

Earnings Waterfall
Silence Therapeutics PLC

Revenue
1.4m GBP
Operating Expenses
-28.6m GBP
Operating Income
-27.2m GBP
Other Expenses
4.8m GBP
Net Income
-22.4m GBP

Free Cash Flow Analysis
Silence Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SLNCF Profitability Score
Profitability Due Diligence

Silence Therapeutics PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Silence Therapeutics PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

SLNCF Solvency Score
Solvency Due Diligence

Silence Therapeutics PLC's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
74/100
Solvency
Score

Silence Therapeutics PLC's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SLNCF Price Targets Summary
Silence Therapeutics PLC

There are no price targets for SLNCF.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SLNCF?

Click here to dive deeper.

Dividends

Silence Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for SLNCF is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Silence Therapeutics PLC Logo
Silence Therapeutics PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

786.2m USD

Dividend Yield

0%

Description

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. The firm is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target for specific disease-associated genes in the liver. The Company’s clinical development programs include SLN360, for the prevalent unmet need in reducing cardiovascular risk in people born with Lipoprotein(a), or Lp(a), levels and SLN124, for rare iron loading anemia conditions, including thalassemia and myelodysplastic syndrome (MDS).

Contact

London
72 Hammersmith Road
+442034576900
www.silence-therapeutics.com

IPO

2010-01-05

Employees

65

Officers

Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
Dr. Giles V. Campion M.D.
Pres, CEO & Director
Mr. Craig A. Tooman M.B.A., MBA
Chief Financial Officer
Ms. Rhonda L. Hellums
Head of IR & Corp. Communications
Ms. Gem Gokmen Hopkins
Sr. VP, Gen. Counsel & Chief Patent Officer
Dr. Barbara A. Ruskin
Chief HR Officer
Mr. Eric Fink
Show More
Sr. VP of Bus. Devel., Alliance Management & New Product Devel.
Dr. John Strafford Ph.D.
Sr. VP & Head of Manufacturing
Mr. Jørgen Wittendorff
Sr. VP of Regulatory Affairs & Quality Assurance
Dr. Eric Floyd Ph.D.
Sr. VP & Head of Molecular Design
Dr. Marie Wikstrom Lindholm Ph.D.
Show Less

See Also

Discover More